Assessment of the Market Opportunity and Optimal Development Path for a Novel Drug in Women’s Health
Client Challenge: The client, a US biotechnology firm, had a novel mid-stage drug – both in terms of MOA and route of administration — for two potential indications in women’s health. The client needed to ensure that the drug had sufficient economic development to warrant development and decide which indication to pursue first.
Our Approach: Working with our client we developed a brief on the drug, including a Target Product Profile and putative clinical trial data, this served as the basis for a series of in-depth interviews with clinicians treating the two indications to understand the level of unmet medical need and the patients for whom they would prescribe the drug. Using this information, as well a review of the current and likely future market, we built a forecast model that allowed us to value each indication and determine the better indication to pursue.
Results: Based on our study, we were able to advise the client on an indication that had both the highest economic value and the clearest and shortest path to regulatory approval. The client used the material we developed to secure next stage funding.